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E-mail address: chiaralamorgia@gmail.com (C. LaIn the last decade, there was the seminal discovery of melanopsin-expressing retinal ganglion cells
(mRGCs) as a new class of photoreceptors that subserve the photoentrainment of circadian rhythms
and other non-image forming functions of the eye. Since then, there has been a growing research interest
on these cells, mainly focused on animal models. Only recently, a few studies have started to address the
relevance of the mRGC system in humans and related diseases.
We recently discovered that mRGCs resist neurodegeneration in two inherited mitochondrial disorders
that cause blindness, i.e. Leber hereditary optic neuropathy and dominant optic atrophy. The mechanism
leading to mRGCs sparing in these blinding disorders, characterized by extensive and selective loss of
RGCs, is currently unknown and under investigation. Other studies reported on mRGCs in glaucoma,
on genetic variation of the melanopsin gene (OPN4) in seasonal affective disorder and on the role of
mRGCs in migraineous photophobia. Our own data and studies from others have shown a signiﬁcant
reduction of mRGCs with aging.
We anticipate that these studies will lead to many other investigations addressing the role of mRGCs
and circadian photoreception in the pathogenesis of circadian and sleep abnormalities in neurodegener-
ative disorders.
 2010 Elsevier Ltd. All rights reserved.1. Introduction and later described in humans referred to as the retinohypotha-Many physiological functions in the human body are character-
ized by rhythmic changes within a 24 h period generated by the
circadian pacemaker, the hypothalamic suprachiasmatic nucleus
(SCN) (Reppert & Weaver, 2002). Studies on the mechanisms of
photoentrainment, i.e. how light adjusts the phase of the circadian
rhythms to the astronomical day length, led to the breakthrough
discovery in 2002 of a third, non-rod non-cone photoreceptor in
the mammalian retina, expressing a photopigment named
melanopsin (Berson, Dunn, & Takao, 2002; Hannibal, Hindersson,
Knudsen, Georg, & Fahrenkrug, 2002; Hattar, Liao, Takao, Berson,
& Yau, 2002; Provencio, Rollag, & Castrucci, 2002). Melanopsin
was identiﬁed in a subtype of retinal ganglion cells (RGCs), which
constitute about 1% of total RGCs (Berson et al., 2002; Dacey et al.,
2005; Hannibal, Hindersson, Nevo, & Fahrenkrug, 2002; Hannibal
et al., 2004; Hattar et al., 2002; Provencio et al., 2000) (Fig. 1).
The melanopsin-expressing RGCs (mRGCs) constitute the
monosynaptic neuronal pathway identiﬁed in mammals by Moore
and Lenn (1972) and Hendrickson, Wagoner, and Cowan (1972)ll rights reserved.
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Morgia).lamic tract (RHT) (Berson et al., 2002; Dacey et al., 2005; Hannibal
et al., 2002; Hattar et al., 2002; Sadun, Schaechter, & Smith, 1984).
It is now well established that mRGCs, through the RHT, mediate
non-image forming functions of the eye, including the photoen-
trainment of circadian rhythms to the light–dark cycle (Guler
et al., 2008; Hatori et al., 2008).
The mRGCs are characterized by unique properties being intrin-
sically photosensitive due to the expression of melanopsin, even in
the absence of any other retinal input (Berson et al., 2002; Hattar
et al., 2002; Lucas et al., 2003). This property allows these cells
to absorb and process light whereas the other RGCs may suffer pos-
sible damage when exposed to direct light energy (Osborne, Li, Ji,
Mortiboys, & Jackson, 2008; Tu et al., 2005). The mRGCs are max-
imally sensitive to short-wavelength blue light (between 459 and
483 nm). Melanopsin is a bistable photopigment, allowing mRGCs
to regenerate their chromophore without involving other cells,
similar to the photoreceptors of invertebrates (Fu et al., 2005;
Mure, Rieux, Hattar, & Cooper, 2007). In fact, the phylogenetic ori-
gin of mRGCs is very ancient and relates to invertebrate rhabdo-
meric photoreception, which predates the development of the
eye as the organ for vision (Peirson, Halford, & Foster, 2009). Thus,
a long-lasting evolutionary pressure conserved this photoreceptive
system, possibly selecting its intrinsic robustness. Moreover,
Fig. 1. Melanopsin expression in a subset of retinal ganglion cells in the human
retina. A ﬂat–mount preparation from a normal part of human retina removed due
to cancer shows melanopsin immunoreactivity in the membrane of the soma and
processes of approximately 1% of retinal ganglion cells forming a photosentitive
network covering the entire retinal surface.
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tionally active at day 0 postnatal, highlighting the importance of
their function in the developing retina (Hannibal & Fahrenkrug,
2004; Tarttelin et al., 2003). Finally, there is now growing evidence
that mRGCs project to many areas of the brain serving many non-
visual forming functions besides photoentrainment of circadian
rhythms, such as regulation of the pupillary light reﬂex, melatonin
secretion and its suppression by light, masking behavior, cognition,
wakefulness and sleep (Berson, 2003; Dijk & Archer 2009; Lupi,
Oster, Thompson, & Foster, 2008; Tsai et al., 2009). These many
functions served by mRGCs are mirrored by their projections,
which not only include the SCN, but also other hypothalamic nu-
clei, such as the ventro-lateral preoptic nucleus that contains sleep
active neurons, and the subparaventricular zone involved in tem-
perature and hormone regulation (Saper, Lu, Chou, & Gooley,
2005). The mRGCs also project to the olivary pretectal nuclei, consti-
tuting the afferent arm of the pupillary light response, the lateral
habenula, a relay site between limbic and striatal areas, the amygdala
involved in regulation of emotions and the intergeniculate leaﬂet of
the thalamus playing a crucial role in mediating the non-photic reg-
ulation of circadian rhythms (Berson, 2003; Hannibal et al., 2004;
Hattar et al., 2006; Vandewalle, Maquet, & Dijk, 2009). The wide-
spread impact of light on the brain also includes the wavelength-
dependent activation of alertness-related subcortical structures such
as the brainstem, and in particular the locus coeruleus, as
documented by functional-MRI studies (Vandewalle et al., 2007a;
Vandewalle et al., 2007b). These cells also provide innervation to
areas of the brain more typically characterized as crucial to vision,
such as the lateral geniculate nucleus and the superior colliculus
(Dacey et al., 2005; Hannibal & Fahrenkrug, 2006; Hattar et al., 2006).
Thus, the recent identiﬁcation of mRGCs came as an important
discovery that contributes greatly to our knowledge of retinal func-
tion, and it has fueled numerous studies aimed at delineating de-
tails of this cellular system with particular reference to
chronobiology. The majority of studies have taken advantage of
animal models by manipulating their genetic expression to deﬁnethe physiology of mRGCs. Some of these studies took advantage of
animal models recapitulating human diseases to infer how patho-
genic mechanisms may involve mRGCs (Vugler, Semo, Joseph, &
Jeffery, 2008). However, to date, only a few studies investigated
the mRGCs-system directly in humans or in human pathology
(Dacey et al., 2005; Hannibal et al., 2004; Vugler et al., 2007).2. Retinal pathology and light-suppression of melatonin led to
the discovery of mRGCs
The discovery of mRGCs came from the observation that mice
with extensive degeneration of rods and cones, such as homozy-
gous (rd/rd) mice lacking rods or mice lacking all functional rod
and cone photoreceptors (rd/rd cl) were still capable of normal cir-
cadian photoentrainment (Foster et al., 1991; Freedman et al.,
1999; Lucas, Freedman, Muñoz, Garcia-Fernández, & Foster,
1999). Moreover, a few studies of human blind subjects with
mixed pathology of rods and cones or optic neuropathy docu-
mented the preservation of the light-induced melatonin suppres-
sion response indicating the existence of a different light
perception system (Czeisler et al., 1995; Hätönen et al., 1998). An
extreme example on the same theme is the completely blind mole
rat Spalax ehrenberghi. This animal, despite the severe regression of
the conventional visual pathways is still able to photoentrain its
circadian rhythms. In fact, there are approximately 900 RGCs still
existent in the mole rat despite its rudimentary subcutaneous eyes
and most of these project to structures in the brain related to cir-
cadian photoreception (Cooper, Herbin, & Nevo, 1993). In this ani-
mal David-Gray and coauthors isolated a cone-like photopigment,
purported to contribute to non-image forming functions
(David-Gray, Janssen, DeGrip, Nevo, & Foster, 1998). Later mela-
nopsin has been recognized as a major pigment in this species
(Hannibal, Hindersson, Nevo, & Fahrenkrug, 2002).
Along the same lines, studies on the action spectrum of light-in-
duced melatonin suppression response in normal human subjects
led to the presumption that a short-wavelength pigment, clearly
different from the photopigments of the classical scotopic and
photopic visual systems, was crucial to mediate this response
(Brainard et al., 2001; Thapan, Arendt, & Skene, 2001). All these
observations were key in the discovery of mRGCs as a new class
of photoreceptors mediating non-image forming functions of the
eye (Berson et al., 2002; Hattar et al., 2002).3. Mitochondrial optic neuropathies: the right model to study
abnormal circadian photoreception?
Human blind subjects have been always considered a useful
model for the study of circadian rhythm disorders (Sack & Lewy,
2001). However, in most studies, subjects enrolled were affected
by heterogeneous retinal pathology and the occurrence of circa-
dian rhythms misalignment was not considered with respect to
the type of retinal disease. Based on the scattered data available,
the occurrence of circadian photoentraiment disturbances seemed
to be determined by the absence of light perception. In fact, the
vast majority (77%) of blind subjects with light perception have
normally entrained circadian rhythms, suggesting a preservation
of the mRGCs–RHT–SCN circuit. In contradistinction, most of the
subjects without light perception, especially those with ocular
enucleation, have abnormal circadian photoentrainment (Skene &
Arendt, 2007). Thus, the presence of circadian rhythm disturbances
seemed to be related to the severity as well as the type of ocular
disease (Wee & Van Gelder, 2004).
Diseases of the outer retina, selectively affecting rods and cones,
and thus sparing themRGCs, were particularly useful to identify the
existence of mRGCs. Similarly, we thought that genetically
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affecting RGCs, would be a good model to study the possible occur-
renceof abnormalities in circadianphotoentrainment. Twosuchdis-
orders, i.e. Leber hereditary optic neuropathy (LHON) and dominant
optic atrophy (DOA) are in fact characterized by the selective loss of
RGCs due to mitochondrial dysfunction (Carelli, Ross-Cisneros, &
Sadun, 2004). Thus, we studied the mRGCs–RHT–SCN system in
LHON and DOA using both a functional, i.e. melatonin suppression
test by light, and a histological approach. We demonstrated that
the mRGCs–RHT–SCN system is substantially unaffected in these
visually impaired patients as they maintain the light-induced sup-
pression of melatonin secretion. Furthermore, our histological
investigation on post-mortem retinal and optic nerve specimens
from LHON and DOA cases demonstrated a relative sparing of
mRGCs (Fig. 2) leading to the unpredicted conclusion that these cells
are resistant to neurodegeneration in mitochondrial optic neuropa-
thies (LaMorgia et al., 2010). These studies suggest the preservation
of circadian photoentrainment in these patients.
Our ﬁndings are compatible with at least two observations.
First, despite LHON and DOA patients are severely visually im-
paired, they usually maintain light perception vision (Carelli
et al., 2004). Second, LHON and DOA patients have also preserved
pupillary light response (Bremner, Tomlin, Shallo-Hoffmann,
Votruba, & Smith, 2001; Wakakura & Yokoe, 1995), which can
now be explained by our ﬁndings of mRGCs sparing. We had pre-
viously shown, in a post-mortem study of a single LHON case with
extremely severe optic atrophy, spared axons leaving the optic chi-
asm and projecting to the pretectum (Bose, Dhillon, Ross-Cisneros,
& Carelli, 2005; Sadun, Win, Ross-Cisneros, Walker, & Carelli,
2000). Also mice with rotenone-induced optic neuropathy, a model
for LHON, preserve the pupillary light reﬂex, suggesting selective
sparing of mRGCs (Zhang, Jones, & Gonzalez-Lima, 2006). Further
indirect conﬁrmation of our results is provided by a single case
study of Kawasaki and coauthors who demonstrated, using selec-
tive wavelength pupillometry in a case of LHON, that the pupil re-
sponse, driven by mRGCs, was spared (Kawasaki, Herbst, Sander, &
Milea, 2010). Furthermore, Pérez-Rico and coauthors (2009) dem-
onstrated, that 5 out of 10 blind subjects maintaining the light-in-
duced melatonin suppression response included 2 DOA subjects.
Our study raises the question of how mRGCs are resistant to
mitochondrial dysfunction. A review of the literature provides a
body of supporting evidence for the resistance of these cells to dif-
ferent kind of injuries. Three studies on the dying-back model of
RGCs after optic nerve transection are revealing. The ﬁrst study
showed that a small subset (about 1%) of surviving RGCs with largeFig. 2. Postmortem human retinas, immunoperoxidase staining for melanopsin, light m
positive retinal ganglion cells (mRGCs) in both the RGC layer (RGCL) and the inner nucle
ND4mutation of mtDNA with severe optic neuropathy. Note the positive staining for a sin
RGCs (as compared to micrograph A). In LHON retinas mRGCs can also be found within the
B, magniﬁcation 400.)bodies intensively stained with cytochrome c oxidase (COX; mito-
chondrial respiratory complex IV) (von Bussmann, Garey, & Jen,
1993); their size and number would be most consistent with
mRGCs. Preliminary data from our laboratory conﬁrm that mRGCs
are intensively stained with both mitochondrial and COX antibod-
ies, suggesting an abundant mitochondrial population within these
cells (Carla Giordano, unpublished results). A more recent study
demonstrated that mRGCs were indeed among the surviving RGCs
after axotomy (Robinson & Madison, 2004) and the last study sug-
gested that involvement of the PI3K/Akt pathway was key to their
survival (Li et al., 2008). Other evidences of mRGCs robustness are
provided by studies on cell toxicity to monosodium glutamate
(Chambille & Serviere 1993; Hannibal, Vrang, Card, & Fahrenkrug,
2001). The neuroprotective role of pituitary adenylate cyclase-acti-
vating polypeptide (PACAP), a neuropeptide speciﬁcally expressed
by mRGCs, has been emphasized by studies on experimental mod-
els of monosodium glutamate toxicity and ocular ischemia (Atlasz
et al., 2008; Seki et al., 2010). Furthermore, the neuroprotective ef-
fect of PACAP administration was also shown in RGCs after optic
nerve transection, providing a plausible candidate for mRGCs resis-
tance to death after axotomy (Seki, Itoh, Nakamachi, & Shioda,
2008).
Our results in mitochondrial optic neuropathies make it tempt-
ing to speculate that spared mRGCs have speciﬁc metabolic prop-
erties and probably have high mitochondrial activity. This is also
suggested by our preliminary results with immunostaining of
mRGCs by mitochondrial and COX antibodies (Carla Giordano,
unpublished results). Intense COX staining has also been demon-
strated by others in surviving RGCs after axotomy (von Bussmann
et al., 1993). The metabolic robustness of mRGCs to mitochondrial
dysfunction may be speciﬁc to complex I impairment, considering
that LHON is due to mitochondrial DNA point mutations affecting
complex I subunits, as well as a mouse model of LHON was ob-
tained by intravitreal injection of rotenone, a classic complex I
inhibitor (Carelli et al., 2004; Zhang et al., 2006). In the latter, the
authors noted the preservation of pupillary light response as in pa-
tients with LHON (Zhang et al., 2006). Moreover, a complex I defect
has also been documented in OPA1 mutant ﬁbroblasts from DOA
patients (Zanna et al., 2008). Complex I dysfunction in mitochon-
drial optic neuropathies has been shown to lead at least to three
pathogenic mechanisms: (1) ATP synthesis driven by complex I-
dependent substrates (malate and glutamate) may be impaired
even if the complex II-dependent pathway can complement this
defect (Carelli et al., 2007). (2) ROS production is chronically in-
creased challenging the antioxidant intra-mitochondrial enzymaticicroscopy; (A) Retina from a normal 58-year-old male demonstrates melanopsin-
ar layer (INL). (B) Retina from a 52-year-old LHON male patient carrying the 11778/
gle mRGC in the RGCL, its dendritic arborization and the absence of non-melanopsin
INL at a similar frequency with normal controls (La Morgia et al., 2010). (Both A and
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oxidase) (Carelli et al., 2007). (3) Cells are sensitized to undergo
apoptosis by shifting the threshold voltage for permeability transi-
tion pore (PTP) opening (Porcelli et al., 2009). Thus, the protection
of mRGCs in comparison to the other RGCs may be mediated
through compensation of any of these mechanisms. Furthermore,
melanopsin-driven photoreception has been reported to trigger
the mobilization of intracellular calcium and, considering the
essential role played by the mitochondrial network in buffering
calcium, we can postulate an important and speciﬁc role played
by mitochondria in the metabolic homeostasis of mRGCs (Hartwick
et al., 2007; Kumbalasiri, Rollag, Isoldi, Castrucci, & Provencio,
2007). The ‘metabolic robustness’ assumed for mRGCs could be de-
rived by a speciﬁc resistance to ROS due to handling of light and
calcium mobilization capability of these cells. The mRGCs photore-
ceptive properties stand in support of this hypothesis. Light expo-
sure to normal RGCs may be directly harmful in the setting of
dysfunctional mitochondria, as in LHON and DOA, by increasing
the ROS-mediated damage (Osborne et al., 2008). We may specu-
late that mRGCs may be intrinsically protected from light damage
and ROS overproduction by expressing the melanopsin photopig-
ment, which absorbs short wavelength light. Thus, melanopsin it-
self may be the other candidate for a neuroprotective role
besides the above mentioned PACAP. At the present stage all these
are speculations and working hypothesis needing solid experimen-
tal proofs.4. Glaucoma optic neuropathy: are mRGCs lost or spared?
Glaucoma is the most common optic neuropathy (Quigley &
Broman, 2006). The late stages of glaucoma are characterized by
an extensive loss of RGCs, which leads to optic atrophy and blind-
ness. Classically, the loss of RGCs in glaucoma follows a physical
pattern selecting for nerve ﬁbers in the arcuate bundles ﬁrst. Re-
cently, the involvement of mRGCs as well as regular RGCs in glau-
coma has been postulated (Jean-Louis, Zizi, Lazzaro & Wolintz,
2008). Indeed, there are two studies in animal models of glaucoma
that suggest a loss of mRGCs or melanopsin photopigment leading
to impairment of circadian rhythms regulation (Drouyer et al.,
2008; Wang et al., 2008). Furthermore, preliminary data in humans
suggested abnormal circadian rhythm of melatonin secretion and
of light-induced melatonin suppression in glaucoma patients
(Cooper et al., 2008; Perez Rico, de la Villa, & Blanco, 2010). Inter-
estingly, the pupillary light reﬂex is also compromised in glaucoma
patients, as documented by pupillographic studies (Kalaboukhova,
Fridhammar, & Lindblom, 2007). However, others have shown that
mRGCs may be spared in some animal models of chronic ocular
hypertension (Jakobs, Libby, Ben, John, & Masland, 2005; Li et al.,
2006).
Thus, further studies are warranted to clarify the involvement
of mRGCs in the natural history of glaucoma, and to investigate
the occurrence of sleep and circadian rhythms abnormalities in pa-
tients with late-stage glaucoma.5. Melanopsin genetics and seasonal affective disorders
A circadian misalignment has been demonstrated in many
mood disorders (Lewy, 2009). The circadian basis for affective dis-
orders is well supported, especially for winter depression, i.e. sea-
sonal affective disorder (SAD), which is characterized by the annual
recurrence of the mood disturbance in fall/winter, with remission
in spring/summer. Abnormalities of hormonal circadian rhythms
have been reported in SAD and light therapy, particularly with blue
light, has been demonstrated as an effective treatment for this dis-
order (Glickman, Byrne, Pineda, Hauck, & Brainard, 2006; Lewyet al., 2009). These data suggest the involvement of the circadian
system and, in particular, of the mechanisms underlying the pho-
toentrainment of circadian rhythms in the pathogenesis of the dis-
ease. These ﬁndings prompted the investigation of the genetic
variation of the OPN4 gene that encodes for melanopsin, and a mis-
sense variant (P10L) was found associated to SAD, suggesting the
possible role of the mRGCs-system in its pathogenesis (Roecklein
et al., 2009).6. Melanopsin and photophobia in migraine
Another recently published study reported on the contribution
of mRGCs to photophobia in migraine (Noseda et al., 2010). This
contribution has been substantiated by the observation that blind
people with light perception, despite the severe defective visual
acuity, maintain photophobia during migraine attacks, at differ-
ence with blind people without light perception (mostly of them
with ocular enucleation). The authors proved, using anterograde
tracing and single-unit recordings, that the synaptic contact with
trigemino-vascular neurons in the posterior thalamus mainly de-
rives from mRGCs, suggesting a major role of the non-image form-
ing system of the retina in mediating migraine-related
photophobia (Noseda et al., 2010). The contribution of mRGCs to
photophobia has also been documented in rodless and coneless
mice (Matynia, Parikh, Chen, Nusinowitz, & Gorin, 2010; Semo
et al., 2010).7. Melanopsin and aging
The aging process is associated with well-documented changes
in sleep. These changes may result from an abnormal homeostatic
regulation of sleep, expressed as an impaired consolidation of
NREM sleep highlighted by a reduction of slow wave activity and
increased awakenings during the night (Dijk, Duffy, & Czeisler,
2000), and/or from a dysfunction of circadian rhythms regulation
(Cajochen, Münch, Knoblauch, Blatter, & Wirz-Justice, 2006). De-
cline in the amplitude of circadian rhythms such as core body tem-
perature, melatonin and cortisol secretion have been reported in
the elderly (Cajochen et al., 2006). Moreover, a phase-advance of
circadian rhythms, in particular of the sleep–wake cycle, and a
shortening of the circadian period are also noted in the elderly
(Carrier, Paquet, Morettini, & Touchette, 2002). Many factors have
been implicated in the occurrence of circadian timing disturbances
with age. Among them we mention: (1) Neurodegenerative
changes in the SCN, i.e. reduction of vasopressin and vasoactive
intestinal peptide expressing neurons. (2) Alterations in the pineal
gland, melatonin levels and melatonin receptors with a decline in
the amplitude of melatonin rhythm and expression of melatonin
receptors (Wu & Swaab, 2007). (3) Reduction of light input to the
SCN due to a decreased capacity of the semicataractous lens to
transmit short wavelength light (Turner & Mainster, 2008). Fur-
thermore, many degenerative changes occur in the retina and optic
nerve with aging (Johnson, Miao, & Sadun, 1987; Chakravarthy,
Evans, & Rosenfeld, 2010).
The contribution of the mRGCs-system to the occurrence of the
circadian misalignment in aging may be more important than ex-
pected. We evaluated post-mortem retinal specimens from con-
trols, comparing two subjects in the mid ﬁfties with one subject
over eighty (La Morgia et al., 2010). We found that mRGCs, as well
as regular RGCs, are lost with age, as previously reported in animal
models and humans (Johnson et al., 1987; Semo, Lupi, Peirson,
Butler, & Foster, 2003; Esquiva et al., 2010). We also showed that
mRGCs are more concentrated around the fovea and this distribu-
tion is maintained with aging despite the general loss of mRGCs
300 C. La Morgia et al. / Vision Research 51 (2011) 296–302(Dacey et al., 2005; Jusuf, Lee, Hannibal, & Grünert, 2007; La
Morgia et al., 2010).
The loss of mRGCs and related impairment of circadian rhythms
and sleep in the elderly is at odds with the metabolic robustness of
mRGCs documented in mitochondrial optic neuropathies particu-
larly since mitochondrial dysfunction is implicated in the aging
process (Trifunovic & Larsson, 2008). This paradox needs to be
investigated.8. Future directions
The role of mRGCs-dependent functions in human pathology is
just beginning to be understood. It is already well established that
loss of these cells may be implicated in the pathogenesis of circa-
dian, sleep, cognitive and mood disorders.
Glaucoma is a key model that needs to be investigated in re-
gards to circadian photoreception in optic neuropathies. Moreover,
retinal dysfunction and RGCs loss has also been documented in
several neurodegenerative diseases including Alzheimer and
Parkinson disease (Archibald, Clarke, Mosimann, & Burn, 2009;
Berisha, Feke, Trempe, McMeel, & Schepens, 2007; Bodis-Wollner,
2009; Hinton, Sadun, Blanks, & Miller, 1986). In both diseases there
is evidence of circadian dysfunction (Willis, Kelly, & Kennedy,
2008; Wu & Swaab, 2007) and efﬁcacy of light as therapy (Burns,
Allen, Tomenson, Duignan, & Byrne, 2009; Paus et al., 2007). A
reasonable link connecting the retinal pathology and circadian dys-
function in Alzheimer and Parkinson disease may be the involve-
ment of mRGCs in the neurodegenerative process.
Preliminary data associating genetic variations of the OPN4
gene with SAD suggests that polymorphic variants of this gene
may also contribute to the human chronotype, i.e. the preference
to be active early or late in the day (morningness/eveningness)
(Roenneberg et al., 2007). Interestingly, melanopsin is implicated
in sleep homeostasis, i.e. build-up of sleep pressure during the
wakefulness, as demonstrated in the Opn4/ mouse model, in
which a signiﬁcant attenuation of electroencephalographic slow
wave activity, a marker of sleep homeostasis, was documented
(Tsai et al., 2009). Similarly, a different sleep homeostatic regula-
tion has been found in morningness/eveningness types, again
potentially linking the role of melanopsin in contributing to the
chronotype (Mongrain, Carrier, & Dumont, 2006; Mongrain &
Dumont, 2007).
It is now well established that many human pathological condi-
tions are responsive to the light stimulation of the circadian pace-
maker (SCN) including circadian rhythm sleep disorders, (delayed
and advanced sleep phase syndrome, shift work disorder, jet lag
and irregular sleep–wake rhythm disorder), age-related sleep dis-
turbances, Alzheimer and Parkinson disease. In all these conditions
light therapy may be effective (Burns et al., 2009; Dowling et al.,
2008; Morgenthaler et al., 2007; Paus et al., 2007). Better deﬁnition
of the parameters of the light sources for light therapy trials is war-
ranted to optimize the efﬁcacy of this approach in stimulating the
mRGCs-system.
The mounting evidence for a direct contribution of mRGCs to vi-
sion may indicate a possible avenue for intervention (Brown, Gigg,
Piggins, & Lucas, 2010; Chen, Ecker, & Hattar, 2010; Dacey et al.,
2005; Gias, Semo, Vugler, & Coffey 2010). The extent to which
mRGCs contribute to visual acuity is not fully deﬁned yet, nor is
the contribution of other recently described opsin-expressing cells
in the inner retina (Semo, Vugler, & Jeffery, 2007). These more re-
cent observations may have important implications for a subset of
blind subjects where mRGCs are spared. This is the case for mito-
chondrial optic neuropathies, such as LHON and DOA, as we have
demonstrated that mRGCs are relatively spared in comparison to
regular RGCs. It would be extremely useful to distinguish the visualacuity driven by the mRGC channel as distinct from that provided
by rods and cones. Currently the physiological separation of these
two pathways has been achieved by a pupillometric protocol in-
tended to elicit the pupillary light response (Park et al., 2010). It
has been shown that awareness of light, i.e. a form of blind sight,
may be evoked in blind patients, such as those lacking an outer ret-
ina, using short-wavelength stimulus, speciﬁc for mRGCs (Zaidi
et al., 2007). Another promising approach has been illustrated
when visual function was partially restored in a mouse model of
retinal degeneration by an ectopic expression of melanopsin into
regular RGCs (Lin, Koizumi, Tanaka, Panda, & Masland 2008).
The recent recognition that mRGCs project to many structures
of the central nervous system contributing to vision, opens the
question of their role in many light-mediated responses, such as
photophobia in migraine. Similarly, photosensitivity and electro-
encephalographic photoparoxysmal responses may be modulated
by the mRGCs projections.
Our studies on mitochondrial optic neuropathies, LHON and
DOA, as well as a few other recent studies on the role of the
mRGCs-system in human patho-physiology gives promise that
the next decade will deliver us many more surprises in the ﬁeld
of melanopsin.References
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